Remitting seronegative symmetrical synovitis with pitting edema

Remitting seronegative symmetrical synovitis with pitting edema
Synonyms	RS3PE
Pronounce	N/A
Specialty	N/A
Symptoms	Synovitis, pitting edema, arthritis
Complications	N/A
Onset	Typically in older adults
Duration	Variable, often remitting
Types	N/A
Causes	Unknown
Risks	Age, possibly genetic predisposition
Diagnosis	Clinical evaluation, exclusion of other conditions
Differential diagnosis	Rheumatoid arthritis, polymyalgia rheumatica, gout
Prevention	N/A
Treatment	Nonsteroidal anti-inflammatory drugs, corticosteroids
Medication	N/A
Prognosis	Generally good with treatment
Frequency	Rare
Deaths	N/A

Remitting Seronegative Symmetrical Synovitis with Pitting Edema (often abbreviated as RS3PE) is a rare clinical syndrome characterized by the onset of acute inflammation in the joints (synovitis) and swelling (edema) in the extremities. The condition is typically seronegative, meaning that it does not show the presence of certain antibodies often associated with rheumatic diseases.

Symptoms[edit]

The primary symptoms of RS3PE include sudden onset of pain and swelling in the joints, particularly in the hands and feet. The swelling often results in a condition known as pitting edema, where pressure applied to the skin leaves a dent that takes some time to fill back in. Other symptoms may include stiffness in the affected joints, fatigue, and in some cases, mild fever.

Causes[edit]

The exact cause of RS3PE is unknown. However, it is believed to be associated with various underlying conditions such as cancer, infections, and autoimmune diseases. Some studies suggest that it may be triggered by an overactive immune response.

Diagnosis[edit]

Diagnosis of RS3PE is primarily based on clinical examination and the patient's medical history. Laboratory tests may be conducted to rule out other conditions. Imaging tests such as ultrasound and magnetic resonance imaging (MRI) may also be used to assess the extent of inflammation and edema.

Treatment[edit]

Treatment for RS3PE typically involves the use of nonsteroidal anti-inflammatory drugs (NSAIDs) to reduce inflammation and pain. In severe cases, corticosteroids may be prescribed. Physical therapy may also be recommended to improve joint function.

Prognosis[edit]

The prognosis for RS3PE is generally good, with most patients experiencing remission within a few months of treatment. However, the condition can recur in some cases.